Children's Hospital, Helsinki University Central Hospital and University of Helsinki, P.O. Box 281, 00029 Helsinki, Finland.
Calcif Tissue Int. 2012 Aug;91(2):121-30. doi: 10.1007/s00223-012-9617-2. Epub 2012 Jun 23.
Previous studies have indicated that children with inflammatory bowel disease (IBD) may not achieve optimal bone mass. We evaluated the skeletal characteristics in children and adolescents with IBD. This cross-sectional cohort study comprised 80 IBD patients (median age 14.9 years, range 5-20) with a median disease duration of 3.4 years; 51 had ulcerative colitis, 26 Crohn disease, and 3 unspecified colitis. Eighty age- and gender-matched healthy subjects served as controls. Areal bone mineral density (aBMD), body composition, and vertebral fractures (VFs) were assessed by DXA. Bone age (BA) was determined for IBD patients. Findings were correlated with disease- and treatment-related parameters and biochemistry. IBD patients had lower BA-adjusted lumbar spine and whole-body aBMD (p < 0.001 for both) and whole-body BMC adjusted for height (p = 0.02) than controls. Lean mass and fat mass Z scores did not differ between the groups, but IBD patients had lower whole-body BMC relative to muscle mass (p = 0.006). Despite vitamin D supplementation in 48 %, vitamin D deficiency was common. In IBD cumulative weight-adjusted prednisolone dose >150 mg/kg for the preceding 3 years increased the risk for low whole-body aBMD (OR = 5.5, 95 % CI 1.3-23.3, p = 0.02). VFs were found in 11 % of patients and in 3 % of controls (p = 0.02). IBD in childhood was associated with low aBMD and reduced bone mass accrual relative to muscle mass; the risk for subclinical VFs may be increased. These observations warrant careful follow-up and active preventive measures.
先前的研究表明,炎症性肠病(IBD)患儿可能无法达到最佳骨量。我们评估了 IBD 患儿和青少年的骨骼特征。这项横断面队列研究包括 80 名 IBD 患者(中位年龄 14.9 岁,范围 5-20 岁),中位疾病病程为 3.4 年;51 名溃疡性结肠炎,26 名克罗恩病,3 名未明确结肠炎。80 名年龄和性别匹配的健康受试者作为对照组。通过 DXA 评估面积骨矿物质密度(aBMD)、身体成分和椎体骨折(VF)。确定 IBD 患者的骨龄(BA)。结果与疾病和治疗相关参数及生物化学指标相关。IBD 患者的 BA 调整后的腰椎和全身体 aBMD 均较低(均 p < 0.001),BA 调整后的全身体重 BMC 也较低(p = 0.02)。两组之间的瘦体重和脂肪量 Z 评分无差异,但 IBD 患者的全身体重 BMC 与肌肉量的比值较低(p = 0.006)。尽管 48%的患者补充了维生素 D,但仍普遍存在维生素 D 缺乏。在 IBD 中,3 年内累积体重调整的泼尼松剂量>150mg/kg 会增加全身体积 aBMD 降低的风险(OR = 5.5,95%CI 1.3-23.3,p = 0.02)。11%的患者和 3%的对照组存在 VF(p = 0.02)。儿童时期的 IBD 与 aBMD 降低和与肌肉量相比骨量积累减少有关;亚临床 VF 的风险可能增加。这些观察结果需要仔细随访和积极的预防措施。